Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on X:
“Our Alliance A221805 trial, published in JCO Oncology Advances, found that duloxetine did not prevent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
Grateful to the patients and research teams who made this study possible.”
Title: Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Authors: Ellen M. Lavoie Smith, Minji Lee, Mary R. Scott, Heshan Liu, Shauna Hillman, Tracy Rieken, Rachel Wills, Julian Diaz-Cobo, Selina Chow, Heidi D. Finnes, Kathryn Ruddy, Jeffrey Meyerhardt, Eileen O’Reilly, Tareq Al Baghdadi, Narjust Florez, Jordan Kharofa, Rang Govindarajan, Mohamedtaki Tejani, Ki Chung, David Zahrieh, Charles Loprinzi, Maryam Lustberg.
Other articles featuring Narjust Florez on OncoDaily.